Abstract
Angiogenesis is the process by which tumours induce a blood supply, crucial for growth and metastasis. Evidence for its role in bladder carcinogenesis, its usefulness as a marker of patient prognosis, and potential anti-angiogenic therapies for future development are discussed in this chapter.
MeSH terms
-
Angiogenesis Inducing Agents / biosynthesis*
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Cyclohexanes
-
DNA-Binding Proteins
-
Drug Combinations
-
Endothelial Growth Factors / biosynthesis
-
Humans
-
Hypoxia-Inducible Factor 1
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
Lymphokines / biosynthesis
-
Mice
-
Mice, Nude
-
Neovascularization, Pathologic / complications*
-
Neovascularization, Pathologic / metabolism
-
Nuclear Proteins
-
O-(Chloroacetylcarbamoyl)fumagillol
-
Piperidines
-
Quinazolines / administration & dosage
-
Quinazolinones
-
Sesquiterpenes / administration & dosage
-
Thymidine Phosphorylase / metabolism
-
Transcription Factors*
-
Urinary Bladder Neoplasms / blood supply*
-
Urinary Bladder Neoplasms / metabolism
-
Urinary Bladder Neoplasms / therapy
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factors
Substances
-
Angiogenesis Inducing Agents
-
Angiogenesis Inhibitors
-
Cyclohexanes
-
DNA-Binding Proteins
-
Drug Combinations
-
Endothelial Growth Factors
-
HIF1A protein, human
-
Hif1a protein, mouse
-
Hypoxia-Inducible Factor 1
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
Lymphokines
-
Nuclear Proteins
-
Piperidines
-
Quinazolines
-
Quinazolinones
-
Sesquiterpenes
-
Transcription Factors
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factors
-
Thymidine Phosphorylase
-
halofuginone
-
O-(Chloroacetylcarbamoyl)fumagillol